Literature DB >> 17413620

Prognosis for patients in a Korean population with ocular adnexal lymphoproliferative lesions.

Jin Sook Yoon1, Kyoung Tak Ma, Sung Joo Kim, Kyunghoon Kook, Sang Yeul Lee.   

Abstract

PURPOSE: To analyze the clinical features, treatment outcomes, and prognostic factors associated with lymphoproliferative lesions of the ocular adnexa in a Korean population.
METHODS: Data from 69 patients treated for adnexal lymphoproliferative disease in the 12-year period from 1991 to 2002 were retrospectively evaluated.
RESULTS: The 69 patients had a median age of 46 years (range, 15-73 years); 60 of these patients were diagnosed with extranodal marginal zone B cell lymphomas (MALT lymphomas) and had 10 year cause specific survival and relapse free survival rates of 95.6% and 82.6%, respectively. Of 6 patients (8.7%) with concurrent systemic lymphoma, including 4 diagnosed with stage IV disease, 3 died from lymphoma. Only one patient with a primary ocular adnexal MALT lymphoma developed systemic lymphoma, which was treated with surgical resection. Local recurrence either at the primary site or in the fellow eye occurred in 11.6% of patients at a median follow-up time of 102 months (range, 79-132 months), and was controlled using repeat irradiation in all cases. Statistical analysis showed the presence of concurrent systemic lymphoma, bilateral disease, and an advanced stage at diagnosis, were linked to lymphoma-related death (Log-rank test, p < 0.05) and systemic progression (Fisher's exact test, p < 0.05), and that the tumor location was not a prognostic factor for lymphoma-related death or relapse at any site.
CONCLUSIONS: Ocular adnexal lymphoproliferative disease in Koreans occurred at a relatively young age, and was mostly orbitally located and of the MALT subtype, which is highly localized and rarely associated with extraorbital relapse. Primary or secondary status, stage at presentation, and bilaterality were found to be prognostic factors.

Entities:  

Mesh:

Year:  2007        PMID: 17413620     DOI: 10.1097/IOP.0b013e318030b058

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  7 in total

Review 1.  Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Authors:  Dimitrios Kalogeropoulos; Alexandra Papoudou-Bai; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Clin Exp Med       Date:  2017-09-22       Impact factor: 3.984

2.  Long-Term Clinical Outcomes in Treatment-Naïve Patients With Orbital Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma: A Single-Center Study.

Authors:  Gi-June Min; Sung Eun Kim; Tong Yoon Kim; Young-Woo Jeon; Joo Hyun O; Byung-Ock Choi; Gyeongsin Park; Suk-Woo Yang; Seok-Goo Cho
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

Review 3.  Extranodal marginal zone lymphoma of the ocular adnexa.

Authors:  Alexandra Stefanovic; Izidore S Lossos
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

4.  Risk potentiality of frontline radiotherapy associated cataract in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Authors:  Won-Kyung Cho; Sung-Eun Lee; Ji-Sun Paik; Seok-Goo Cho; Suk-Woo Yang
Journal:  Korean J Ophthalmol       Date:  2013-07-05

Review 5.  Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors.

Authors:  Sung Yong Oh; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 3.165

6.  Genome-wide DNA methylation profiles according to Chlamydophila psittaci infection and the response to doxycycline treatment in ocular adnexal lymphoma.

Authors:  Min Joung Lee; Byung-Joo Min; Ho-Kyung Choung; Namju Kim; Young A Kim; Sang In Khwarg
Journal:  Mol Vis       Date:  2014-07-19       Impact factor: 2.367

7.  Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study.

Authors:  Sung-Yong Kim; Suk-Woo Yang; Won-Sik Lee; Jae Wook Yang; Sung Yong Oh; Hee Bae Ahn; Deok-Hwan Yang; Seong Kyu Park; Jee Ho Chang; Hyo Jung Kim; Min Joung Lee; Seok-Goo Cho
Journal:  Oncotarget       Date:  2017-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.